glp 1 noom Microdosing GLP-1 for Weight Loss Why We Launched Noom GLP-1RX

GLP-1 receptor agonists and cardiovascular outcome trials: An update

Longer-term concerns include a potential increased risk of pancreatitis, bowel obstruction, and thyroid cancer

While the weight loss numbers are currently modest compared to tirzepatide, the liver-specific benefits could make pemvidutide particularly valuable for people with fatty liver disease

Meanwhile, Eli Lilly is also being sued by past Zepbound patients who claim they suffered from an eye stroke (NAION) that caused them to go blind

Furthermore, pemvidutide is currently undergoing Phase II studies for various Metabolic Syndrome Hybrid Disorders (MASH)

GLP-1 clinical trial results GLP-1 medications have consistently demonstrated greater weight loss in clinical trials